18F-FDG PET/CT Prediction of Treatment Outcomes in Human Papillomavirus–Positive, Locally Advanced Oropharyngeal Cancer Patients Receiving Deintensified Therapy: Results from NRG-HN002
暂无分享,去创建一个
J. Waldron | K. Sultanem | S. Yom | Q. Le | L. Mell | W. Thorstad | J. Chan | J. Beitler | J. Caudell | M. Gillison | M. Truong | R. Subramaniam | J. Geiger | M. Echevarria | M. Yao | S. Seaward | L. Demora | Ping Xia | Christine Chung | Diagjin Blakaj
[1] Yingming Sun,et al. Therapeutic strategies of different HPV status in Head and Neck Squamous Cell Carcinoma , 2021, International journal of biological sciences.
[2] Christopher U. Jones,et al. Reduced-Dose Radiation Therapy for HPV-Associated Oropharyngeal Carcinoma (NRG Oncology HN002) , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] A. Jemal,et al. Cancer Statistics, 2021 , 2021, CA: a cancer journal for clinicians.
[4] T. Van den Wyngaert,et al. Quality Assessment in FDG-PET/CT Imaging of Head-and-Neck Cancer: One Home Run Is Better Than Two Doubles , 2020, Frontiers in Oncology.
[5] P. Ha,et al. De-intensification strategies in HPV-related oropharyngeal squamous cell carcinoma—a narrative review , 2020, Annals of translational medicine.
[6] A. Scarsbrook,et al. Post-treatment FDG PET-CT in head and neck carcinoma: comparative analysis of 4 qualitative interpretative criteria in a large patient cohort , 2020, Scientific Reports.
[7] A. Maes,et al. Quantification of 18F-fluorodeoxyglucose uptake to detect residual nodal disease in locally advanced head and neck squamous cell carcinoma after chemoradiotherapy: results from the ECLYPS study , 2020, European Journal of Nuclear Medicine and Molecular Imaging.
[8] Kevin P. Banks,et al. RESISTing the Need to Quantify: Putting Qualitative FDG-PET/CT Tumor Response Assessment Criteria into Daily Practice , 2019, American Journal of Neuroradiology.
[9] D. Schuster,et al. Head and neck PET/CT therapy response interpretation criteria (Hopkins criteria) - external validation study. , 2017, American journal of nuclear medicine and molecular imaging.
[10] O. Hoekstra,et al. Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography After Concurrent Chemoradiotherapy in Locally Advanced Head-and-Neck Squamous Cell Cancer: The ECLYPS Study. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] C. McConkey,et al. PET-CT Surveillance versus Neck Dissection in Advanced Head and Neck Cancer. , 2016, The New England journal of medicine.
[12] Carole Fakhry,et al. Epidemiology of Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] R. Wahl,et al. Head and Neck PET/CT: Therapy Response Interpretation Criteria (Hopkins Criteria)—Interreader Reliability, Accuracy, and Survival Outcomes , 2014, The Journal of Nuclear Medicine.
[14] V. Grégoire,et al. Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial. , 2012, The Lancet. Oncology.
[15] K. Ang,et al. Human papillomavirus and survival of patients with oropharyngeal cancer. , 2010, The New England journal of medicine.
[16] R. Wahl,et al. From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors , 2009, Journal of Nuclear Medicine.